DBV Technologies shares decline nearly 3%, among the largest drops in the SBF 120

A stock below its three moving averages, with an RSI at 35

DBV Technologies declines 2.78% to €1.85 in trading, placing it among the largest drops in the SBF 120, an index losing 0.94%. The decline brings the stock's three-month loss to 36.04%, following a -19.73% decline over the last month alone. The price stands 13.10% below the MA20 (€2.13) and 40.10% below the MA200 (€3.09).

The RSI at 35 remains close to the oversold zone without entering it, while the support level at €1.92, now breached, gives way to an absence of immediate technical floor. The filing of the biological license application with the FDA for the peanut allergy patch, announced on September 30, had sparked a rebound on the same day. The stock erased it as early as October 1 by falling back below €2.

Cumulative short positions climb to 4.40% of capital

According to the declarations reviewed, four funds cumulate 4.40% of capital in net short position, compared to 3.51% thirty days ago. The increase of 0.89 percentage points in one month shows that the bearish bet is strengthening without accelerating. These positions indicate that institutional investors remain positioned against the stock, or are seeking to hedge an exposure, a few months ahead of a regulatory deadline that remains the primary source of information on the file.

In its latest results, published on July 16 for the first half of 2026, the company stated it had cash reserves ensuring financing through the third quarter of 2027. It generates still marginal revenue, with the progress of the FDA file constituting the main benchmark for the market.